Clinical Trials Logo

Pancreatic Neoplasms clinical trials

View clinical trials related to Pancreatic Neoplasms.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT06017323 Withdrawn - Clinical trials for Metastatic Pancreatic Cancer

Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma

ProglumidePanc
Start date: October 2023
Phase: Phase 1
Study type: Interventional

This is a Phase I open labelled study to treat patients with metastatic pancreatic cancer with combination therapy using standard of care first line therapy with gemcitabine and nab-paclitaxel given days 1, 8, and 15 every 28 days, and proglumide. This is a phase 1 study with 3+3 design, enrolling3-12 patients over 2 planned dose levels of proglumide(maximum 6 patients per dose level). Proglumide will be tested at the daily dose of 1200 mg orally (PO) given as 400mg three times daily (TID) (dose level 1) or 1600 mg orally(PO) given as 800 mg twice a day (BID) (dose level 2). All cycles are 28 days. Patients will be monitored for safety and toxicity by laboratory blood testing and physical examinations.

NCT ID: NCT05702385 Withdrawn - Pancreas Cancer Clinical Trials

Clinical Utility Study for Exo-PDAC

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

This is a national-level research study of oncologists, interventional gastroenterologists, and primary care providers. The purpose of this study is to assess the clinical evaluation and management (drug, procedures, counseling and other) of a subset of common patient care indications.

NCT ID: NCT05465590 Withdrawn - Breast Cancer Clinical Trials

A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer

Start date: December 2022
Phase: Early Phase 1
Study type: Interventional

The study will evaluate the pharmacokinetics (PK) and safety of a single intravenous (IV) dose of 0.3 mg/kg MB1707 in patients with advanced cancers.

NCT ID: NCT05379907 Withdrawn - Pancreatic Cancer Clinical Trials

Observational Study of ctDNA in Resectable and Borderline Resectable Pancreatic Cancer

Start date: August 23, 2022
Phase:
Study type: Observational

The purpose of this study is to collect information about treatment recommendations based on ctDNA testing and whether treatment changes based on ctDNA information result in better outcomes for patients with pancreatic cancer.

NCT ID: NCT05360745 Withdrawn - Quality of Life Clinical Trials

Quality of Life With Nutritional Supplementation in Patients With Locally Advanced/Metastatic Pancreatic Cancer.

FOODPANC
Start date: June 29, 2022
Phase: N/A
Study type: Interventional

Metastatic pancreatic cancer has a poor prognosis, with approximately one-third of patients experiencing poor quality of life at six months. ARACOMPLEX® is a food supplement that contains maca extract, vitamin complexes and ions, and this nutritional contribution seems to favor the improvement of the patient's quality of life. To verify this statement, this experimental study is carried out in patients with locally advanced/metastatic pancreatic cancer.

NCT ID: NCT05251038 Withdrawn - Pancreatic Cancer Clinical Trials

Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer

Start date: September 13, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, non-randomized, open-label, phase Ib/II study to evaluate the safety, tolerability and efficacy of sotorasib in combination with chemotherapy for patients with advanced KRAS p.G12C mutant pancreatic cancer with progression of disease after first line treatment. There will be a safety lead in to determine the safety and tolerability of the sotorasib in combination with standard chemotherapy. A Simon two-stage design will be employed to evaluate the efficacy of sotorasib in combination with standard of care second line chemotherapy.

NCT ID: NCT05238831 Withdrawn - Clinical trials for Recurrent Ovarian Carcinoma

SMMART Adaptive Clinical Treatment (ACT) Trial

Start date: January 30, 2023
Phase: Early Phase 1
Study type: Interventional

SMMART-ACT is a feasibility pilot study to determine if testing samples from a participant's cancer using a precision medicine approach can be used to identify specific drugs or drug combinations that can help control their disease. The safety and tolerability of the drug or drug combination is also to be studied. Another purpose is for researchers to study tumor cells to try to learn why some people respond to a certain therapy and others do not, and why some cancer drugs stop working. The study population will include participants with advanced breast, ovarian, prostate, or pancreatic malignancies, or sarcomas.

NCT ID: NCT05216120 Withdrawn - Pancreas Cancer Clinical Trials

Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas

Start date: June 14, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this research is to determine the benefit of pemigatinib in patients with advanced metastatic or surgically unresectable adenosquamous carcinoma of the pancreas who have progressed on previous therapy.

NCT ID: NCT05212025 Withdrawn - Pancreatic Cancer Clinical Trials

Adavosertib and Gemcitabine in Advanced Pancreatic

Start date: June 2022
Phase: Phase 2
Study type: Interventional

This study is being done to test the safety and effectiveness of combining Adavosertib and Gemcitabine in patients with pancreatic cancer. The names of the study drugs involved in this study are: - Adavosertib - Gemcitabine

NCT ID: NCT05181865 Withdrawn - Gastric Cancer Clinical Trials

Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors

Start date: January 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2a, first-in-human, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of FL-301 in patients with advanced cancer.